arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Enovis CORP

ENOV
$28.63 ▲ +4.22 (+17.29%) at close
Healthcare ·Orthopedic, Prosthetic & Surgical Appliances & Supplies ·USOrthopedic, Prosthetic & Surgical Appliances & Supplies
17 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

Enovis CORP faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.6B
Dividend Yield —
Revenue Growth 6.7% ↘
Op. Margin -50.0% ↘
ROIC -41.1% ↘
FCF / Share $0.35 ↗
Trailing P/E —
Price / Book 1.1x
FCF Yield 1.2%
Debt / Equity 0.87
info Valuation on last close. End-of-day price, Nov 5, 2026.

17-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.25B
↑ +6.7% —
Net Income Profit after all expenses
$-1.18B
↓ -43.5% —
Operating Margin Operating profit as % of sales
-50.0%
↓ -35.9% 5th
FCF / Share Free cash flow per share
$0.35
↑ +128.7% —
Long-Term Debt Long-term obligations
$1.30B
↓ -2.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
12
Returns
11
Financial Health →
27
Cash Quality
21

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 17 years · 64 quarters